Journal of Thrombosis and Haemostasis

Atherothrombosis risk factors: too many and too little
pp. 1793-1794(2)
Author: EMMERICH, J.

A comparison of the associations between seven hemostatic or inflammatory variables and coronary heart disease
pp. 1795-1800(6)
Authors: WOODWARD, M.; RUMLEY, A.; WELSH, P.; MACMAHON, S.; LOWE, G.

Neonatal immune tolerance for hemophilia: can we `tolerate' new paradigms for gene therapy trials?
pp. 1801-1804(4)
Author: MONAHAN, P. E.

High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice
pp. 1805-1812(8)
Authors: XU, L.; MEI, M.; MA, X.; PONDER, K. P.

Multiple roles of the endothelial cell protein C receptor
pp. 1813-1816(4)
Author: CRAWLEY, J. T. B.

Binding of factor VIIa to the endothelial cell protein C receptor reduces its coagulant activity
pp. 1817-1824(8)
Authors: LÓPEZ-SAGASETA, J.; MONTES, R.; PUY, C.; DÍEZ, N.; FUKUDOME, K.; HERMIDA, J.

Antiphospholipid syndrome: new light comes from in vivo studies
pp. 1825-1827(3)
Author: FORASTIERO, R.

Role of p38 mitogen-activated protein kinase in antiphospholipid antibody-mediated thrombosis and endothelial cell activation
pp. 1828-1834(7)
Authors: VEGA-OSTERTAG, M. E.; FERRARA, D. E.; ROMAY-PENABAD, Z.; LIU, X.; TAYLOR, W. R.; COLDEN-STANFIELD, M.; PIERANGELI, S. S.

Platelet function, antiplatelet therapy and clinical outcomes: to test or not to test?
pp. 1835-1838(4)
Authors: DE GAETANO, G.; CERLETTI, C.

Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients
pp. 1839-1847(9)
Authors: PANICCIA, R.; ANTONUCCI, E.; GORI, A. M.; MARCUCCI, R.; GIGLIOLI, C.; ANTONIUCCI, D.; GENSINI, G. F.; ABBATE, R.; PRISCO, D.

Efficacy of inferior vena cava filters in anticoagulated patients
pp. 1848-1853(6)
Authors: BILLETT, H. H.; JACOBS, L. G.; MADSEN, E. M.; GIANNATTASIO, E. R.; MAHESH, S.; COHEN, H. W.

Fondaparinux combined with intermittent pneumatic compression vs. intermittent pneumatic compression alone for prevention of venous thromboembolism after abdominal surgery: a randomized, double-blind comparison
pp. 1854-1861(8)
Authors: TURPIE, A. G. G.; BAUER, K. A.; CAPRINI, J. A.; COMP, P. C.; GENT, M.; MUNTZ, J. E.

Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients
pp. 1862-1868(7)
Authors: FERNANDEZ-CADENAS, I.; ALVAREZ-SABIN, J.; RIBO, M.; RUBIERA, M.; MENDIOROZ, M.; MOLINA, C. A.; ROSELL, A.; MONTANER, J.

Influence of age on the cost-effectiveness of diagnostic strategies for suspected pulmonary embolism
pp. 1869-1877(9)
Authors: RIGHINI, M.; NENDAZ, M.; LE GAL, G.; BOUNAMEAUX, H.; PERRIER, A.

Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study
pp. 1878-1882(5)
Authors: NIERS, T. M. H.; DI NISIO, M.; KLERK, C. P. W.; BAARSLAG, H. J.; BÜLLER, H. R.; BIEMOND, B. J.

Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases
pp. 1883-1889(7)
Authors: SWADŹBA, J.; IWANIEC, T.; SZCZEKLIK, A.; MUSIAŁ, J.

Effect of leg exercises on popliteal venous blood flow during prolonged immobility of seated subjects: implications for prevention of travel-related deep vein thrombosis
pp. 1890-1895(6)
Authors: HITOS, K.; CANNON, M.; CANNON, S.; GARTH, S.; FLETCHER, J. P.

The plasma kallikrein-kinin system and risk of cardiovascular disease in men
pp. 1896-1903(8)
Authors: GOVERS-RIEMSLAG, J. W. P.; SMID, M.; COOPER, J. A.; BAUER, K. A.; ROSENBERG, R. D.; HACK, C. E.; HAMULYAK, K.; SPRONK, H. M. H.; MILLER, G. J.; TEN CATE, H.

Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors
pp. 1904-1913(10)
Authors: KONKLE, B. A.; EBBESEN, L. S.; ERHARDTSEN, E.; BIANCO, R. P.; LISSITCHKOV, T.; RUSEN, L.; SERBAN, M. A.

Challenges in defining type 2M von Willebrand disease: results from a Canadian cohort study
pp. 1914-1922(9)
Authors: JAMES, P. D.; NOTLEY, C.; HEGADORN, C.; POON, M.-C.; WALKER, I.; RAPSON, D.; LILLICRAP, D.

A collaborative study to establish the 1st International Standard for factor XIII plasma
pp. 1923-1929(7)
Authors: RAUT, S.; MERTON, R. E.; RIGSBY, P.; MUSZBEK, L.; SEITZ, R.; ARIËNS, R. A. S.; BARROWCLIFFE, T. W.; ICHINOSE, A.

A genetic basis for the interrelation of coagulation factors
pp. 1930-1935(6)
Authors: VOSSEN, C. Y.; CALLAS, P. W.; HASSTEDT, S. J.; LONG, G. L.; ROSENDAAL, F. R.; BOVILL, E. G.

Systemic administration of anti-urokinase plasminogen activator receptor monoclonal antibodies induces hepatic fibrin deposition in tissue-type plasminogen activator deficient mice
pp. 1936-1944(9)
Authors: JÖGI, A.; PASS, J.; HØYER-HANSEN, G.; LUND, L. R.; NIELSEN, B. S.; DANØ, K.; RØMER, J.

Proteomic analysis of platelet α-granules using mass spectrometry
pp. 1945-1955(11)
Authors: MAYNARD, D. M.; HEIJNEN, H. F. G.; HORNE, M. K.; WHITE, J. G.; GAHL, W. A.

Characterization of the interaction between von Willebrand factor and osteoprotegerin
pp. 1956-1962(7)
Authors: SHAHBAZI, S.; LENTING, P. J.; FRIBOURG, C.; TERRAUBE, V.; DENIS, C. V.; CHRISTOPHE, O. D.

Two novel monoclonal antibodies to VWFA3 inhibit VWF-collagen and VWF-platelet interactions
pp. 1963-1970(8)
Authors: ZHAO, Y.; DONG, N.; SHEN, F.; XIE, L.; HE, Y.; LIU, F.; RUAN, C.

Scientific and standardization committee communications: classification and nomenclature of disintegrins isolated from snake venoms
pp. 1971-1971(1)
Authors: MCLANE, M. A.; PAQUETTE-STRAUB, C.

Scott syndrome dogs have impaired coated-platelet formation and calcein-release but normal mitochondrial depolarization
pp. 1972-1974(3)
Authors: BROOKS, M. B.; CATALFAMO, J. L.; FRIESE, P.; DALE, G. L.

The cost-effectiveness of warfarin pharmacogenomics
pp. 1974-1975(2)
Author: VEENSTRA, D. L.

Effect of daptomycin on prothrombin time and the requirement for outlier exclusion in International Sensitivity Index calibration of thromboplastin
pp. 1975-1976(2)
Authors: VAN DEN BESSELAAR, A. M. H. P.; TRIPODI, A.

Mg²⁺ binding to the Gla domain of factor X influences the interaction with tissue factor
pp. 1977-1978(2)
Authors: PERSSON, E.; ØSTERGAARD, A.

Current practise of testing for inherited thrombophilia
pp. 1979-1981(3)
Authors: COPPENS, M.; VAN MOURIK, J. A.; ECKMANN, C. M.; BÜLLER, H. R.; MIDDELDORP, S.

Phenotypic and genotypic differences in factor XII between African Americans and Caucasians
pp. 1981-1982(2)
Authors: MILLER, C. H.; HOOPER, C.

Influence of argatroban on coagulation parameters in heparin-induced thrombocytopenia patients after cardiothoracic surgery
pp. 1982-1984(3)
Authors: HARDER, S.; MERZ, M.; KLINKHARDT, U.; LORENZ, H.; KOSTER, A.

Once-daily enoxaparin in pediatric thromboembolism: a dose finding and pharmacodynamics/pharmacokinetics study
pp. 1985-1987(3)
Authors: O'BRIEN, S. H.; LEE, H.; RITCHEY, A. K.

Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine
pp. 1988-1990(3)
Authors: UNDAS, A.; PLICNER, D.; STĘPIEŃ, E.; DRWIŁA, R.; SADOWSKI, J.

Outcome of the subsequent pregnancy after a first loss in women with factor V Leiden or prothrombin 20210A mutation: a rebuttal
pp. 1990-1992(3)
Authors: LISSALDE-LAVIGNE, G.; MARÈS, P.; QUÉRÉ, I.; GRIS, J.-C.

Outcome of the subsequent pregnancy after a first loss in women with the factor V Leiden or prothrombin 20210A mutation: reply to a rebuttal
pp. 1992-1994(3)
Authors: COPPENS, M.; FOLKERINGA, N.; TEUNE, M. J.; HAMULYÁK, K.; VAN DER MEER, J.; PRINS, M. H.; BÜLLER, H. R.; MIDDELDORP, S.

CORRIGENDA
pp. 1995-1995(1)

CORRIGENDA
pp. 1995-1995(1)

ANNOUNCEMENTS
pp. 1996-1996(1)